JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML
Riikka Karjalainen(University of Helsinki), Caroline A. Heckman(University of Helsinki)
Cited by 122
Related Papers
Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
|Haematologica|2019|184
The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis
|Cancer Research|2008|117
Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling
|Oncotarget|2017|31